Neurocrine Biosciences (NBIX) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Neurocrine Bio. (NBIX) PT Lowered to $105 at Cowen
February 6, 2019 7:54 AM ESTCowen analyst Phil Nadeau lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $105.00 (from $115.00) while maintaining a Outperform rating.
The analyst commented, "NBIX reported Q4 Ingrezza sales of $130.3MM, consistent with its January pre-announcement. Results from NBI-74788's Ph. IIa in CAH... More
